{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T08:53:18Z","timestamp":1782463998585,"version":"3.54.5"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>While nutrient-stimulated hormone (NuSH) therapies (e.g., glucagon-like pepide-1 receptor agonists and dual\/triple agonists) have transformed the landscape of obesity pharmacotherapy, the next generation of medications may target body composition optimization or other cardiovascular benefits. This review examines novel obesity mechanisms outside of the NuSH class.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Unique mechanisms for obesity treatment include peripherally restricted cannabinoid-1 receptor antagonism, myostatin\/activin inhibitors, selective androgen receptor modulators, melanocortin-4 receptor agonism, mitochondrial modulation, thyroid receptor agonists, and fibroblast growth factor analogues. By targeting fat distribution, muscle preservation, inflammatory\/oxidative stress pathways, lipid metabolism, and energy expenditure, these agents may improve both the magnitude and quality of weight loss. Early evidence suggests complementary roles alongside NuSH-based therapies for induction, augmentation, and maintenance strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Several non-NuSH agents have demonstrated potential in preclinical and early clinical studies to optimize body composition, but additional studies are required to prove large-scale, long-term safety and efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11883-026-01438-8","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T08:41:24Z","timestamp":1782463284000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Overview of Novel Mechanisms in Obesity Pharmacotherapy and Implications for Cardiovascular Disease: A Narrative Review"],"prefix":"10.1007","volume":"28","author":[{"given":"Michael","family":"Bonafede","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2955-8089","authenticated-orcid":false,"given":"Beverly G.","family":"Tchang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"1438_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.14797\/mdcvj.1528","volume":"21","author":"I Shahid","year":"2025","unstructured":"Shahid I, Zakaria F, Chang R, et al. Obesity and atherosclerotic cardiovascular disease: a review of social and biobehavioral pathways. Methodist DeBakey Cardiovasc J. 2025;21:23\u201334. https:\/\/doi.org\/10.14797\/mdcvj.1528.","journal-title":"Methodist DeBakey Cardiovasc J"},{"key":"1438_CR2","doi-asserted-by":"publisher","first-page":"e320","DOI":"10.1016\/j.jacl.2024.04.001","volume":"18","author":"HE Bays","year":"2024","unstructured":"Bays HE, Kirkpatrick CF, Maki KC, et al. Obesity, dyslipidemia, and cardiovascular disease: a joint expert review from the Obesity Medicine Association and the National Lipid Association 2024. J Clin Lipidol. 2024;18:e320\u201350. https:\/\/doi.org\/10.1016\/j.jacl.2024.04.001.","journal-title":"J Clin Lipidol"},{"key":"1438_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa1212914","volume":"369","author":"AHEADR Look","year":"2013","unstructured":"Look AHEADR, Group, Wing RR, Bolin P, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145\u201354. https:\/\/doi.org\/10.1056\/NEJMoa1212914.","journal-title":"N Engl J Med"},{"key":"1438_CR4","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S2213-8587(16)30162-0","volume":"4","author":"AHEADR Look","year":"2016","unstructured":"Look AHEADR, Group, Gregg EW, Jakicic JM, et al. Association of weight loss and physical fitness with long-term cardiovascular outcomes in type 2 diabetes: a post hoc analysis of the Look AHEAD trial. Lancet Diabetes Endocrinol. 2016;4:913\u201321. https:\/\/doi.org\/10.1016\/S2213-8587(16)30162-0.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1438_CR5","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2307563.","journal-title":"N Engl J Med"},{"key":"1438_CR6","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","volume":"404","author":"J Deanfield","year":"2024","unstructured":"Deanfield J, Verma S, Scirica BM, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024;404:773\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(24)01498-3.","journal-title":"Lancet"},{"key":"1438_CR7","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1002\/oby.23902","volume":"31","author":"M Morningstar","year":"2023","unstructured":"Morningstar M, Kolodziej A, Ferreira S, et al. Novel cannabinoid receptor 1 inverse agonist CRB\u2010913 enhances efficacy of tirzepatide, semaglutide, and liraglutidein the diet\u2010induced obesity mouse model. Obesity Silver Spring. 2023;31:2676\u201388. https:\/\/doi.org\/10.1002\/oby.23902.","journal-title":"Obesity Silver Spring"},{"key":"1438_CR8","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1172\/JCI42551","volume":"120","author":"J Tam","year":"2010","unstructured":"Tam J, Vemuri VK, Liu J, et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest. 2010;120:2953\u201366. https:\/\/doi.org\/10.1172\/JCI42551.","journal-title":"J Clin Invest"},{"key":"1438_CR9","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/dom.15488","volume":"26","author":"G Crater","year":"2024","unstructured":"Crater G, et al. County\u2010level socio\u2010environmental factors and obesity prevalence in the United States. Diabetes Obes Metab. 2024;26:1090\u20137. https:\/\/doi.org\/10.1111\/dom.15488.","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 1","key":"1438_CR10","doi-asserted-by":"publisher","DOI":"10.2337\/db25-1716-P","volume":"74","author":"F Ruiz-Pino","year":"2025","unstructured":"Ruiz-Pino F, Mu\u00f1oz E, Ponce-D\u00edaz FJ, et al. 1716-P: Nimacimab, a peripherally restricted CB1 inhibitor, promotes metabolic homeostasis in a diet-induced obesity (DIO) mouse model as demonstrated by weight loss, restored hormonal regulation, and reduced inflammatory biomarkers. Diabetes. 2025;74(Suppl 1):1716-P. https:\/\/doi.org\/10.2337\/db25-1716-P.","journal-title":"Diabetes"},{"key":"1438_CR11","unstructured":"Skye Bioscience Inc. Top-line CBeyond\u2122 phase 2a data for nimacimab in obesity. In: Skye Bioscience. 2025. https:\/\/www.skyebioscience.com. Accessed 1 Nov 2025."},{"key":"1438_CR12","doi-asserted-by":"publisher","unstructured":"Lach-Trifilieff E, et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat Med. 2014;126. https:\/\/doi.org\/10.1038\/nm.3444.","DOI":"10.1038\/nm.3444"},{"key":"1438_CR13","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1016\/j.biocel.2013.05.019","volume":"45","author":"HQ Han","year":"2013","unstructured":"Han HQ, Zhou X, Mitch WE, Goldberg AL. Myostatin\/activin pathway antagonism: molecular basis and therapeutic potential. Int J Biochem Cell Biol. 2013;45:2333\u201347. https:\/\/doi.org\/10.1016\/j.biocel.2013.05.019.","journal-title":"Int J Biochem Cell Biol"},{"issue":"1","key":"1438_CR14","doi-asserted-by":"publisher","first-page":"e2033457","DOI":"10.1001\/jamanetworkopen.2020.33457","volume":"4","author":"SB Heymsfield","year":"2021","unstructured":"Heymsfield SB, et al. Effect of Bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity. JAMA Netw Open. 2021;4:e2033457. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.33457.","journal-title":"JAMA Netw Open"},{"key":"1438_CR15","unstructured":"Regeneron Pharmaceuticals. Interim results from the phase 2 COURAGE trial. In: Regeneron. 2025. https:\/\/www.regeneron.com. Accessed 1 Nov 2025."},{"key":"1438_CR16","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1210\/endrev\/bnaa037","volume":"42","author":"JT Dalton","year":"2021","unstructured":"Dalton JT, et al. Selective androgen receptor modulators in clinical trials. Endocr Rev. 2021;42:240\u201356. https:\/\/doi.org\/10.1210\/endrev\/bnaa037.","journal-title":"Endocr Rev"},{"key":"1438_CR17","unstructured":"Halsey G. Enobosarm preserves lean mass with semaglutide: phase 2b data. In: Patient Care Online. 2025. https:\/\/www.patientcareonline.com. Accessed 1 Nov 2025."},{"key":"1438_CR18","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1210\/er.2009-0037","volume":"31","author":"YX Tao","year":"2010","unstructured":"Tao YX. The melanocortin-4 receptor pathway in obesity. Endocr Rev. 2010;31:506\u201343. https:\/\/doi.org\/10.1210\/er.2009-0037.","journal-title":"Endocr Rev"},{"key":"1438_CR19","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/dom.14647","volume":"24","author":"C Spana","year":"2022","unstructured":"Spana C, Jordan R, Fischkoff S. Persistence with insulin pump therapy among children and young adults with type 1 diabetes in Germany: an update. Diabetes Obes Metab. 2022;24:1084\u201393. https:\/\/doi.org\/10.1111\/dom.14647.","journal-title":"Diabetes Obes Metab"},{"key":"1438_CR20","unstructured":"Palatin Technologies Inc. Bremelanotide with tirzepatide meets phase 2 endpoint. In: Palatin Technologies. 2025. https:\/\/www.palatint.com. Accessed 1 Nov 2025."},{"key":"1438_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/biom13040687","volume":"13","author":"D Sulaiman","year":"2023","unstructured":"Sulaiman D, et al. Vutiglabridin modulates paraoxonase 1 and ameliorates diet-induced obesity in hyperlipidemic mice. Biomolecules. 2023;13:687. https:\/\/doi.org\/10.3390\/biom13040687.","journal-title":"Biomolecules"},{"issue":"1","key":"1438_CR22","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41366-020-00686-1","volume":"45","author":"LS Choi","year":"2021","unstructured":"Choi LS, Jo IG, Kang KS, et al. Discovery and preclinical efficacy of HSG4112, a synthetic structural analog of glabridin, for the treatment of obesity. Int J Obes. 2021;45(1):130\u201342. https:\/\/doi.org\/10.1038\/s41366-020-00686-1.","journal-title":"Int J Obes"},{"key":"1438_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118759","volume":"193","author":"HM Lee","year":"2025","unstructured":"Lee HM, Lee JH, Kim SH, et al. Vutiglabridin ameliorates obesity by directly reducing fat mass through AMPK\/lipophagy activation in adipocytes. Biomed Pharmacother. 2025;193:118759. https:\/\/doi.org\/10.1016\/j.biopha.2025.118759.","journal-title":"Biomed Pharmacother"},{"key":"1438_CR24","doi-asserted-by":"publisher","unstructured":"Na JY, et al. Non\u2010synonymous alterations in AKR7A3 and ABCA6 correlate with bleeding in aged patients treated with rivaroxaban. Clin Transl Sci. 2022;1185. https:\/\/doi.org\/10.1111\/cts.13205.","DOI":"10.1111\/cts.13205"},{"key":"1438_CR25","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1111\/cts.13401","volume":"15","author":"JY Na","year":"2022","unstructured":"Na JY, Yoon DY, Yoo H, et al. Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: a first\u2010in\u2010class, first\u2010in\u2010human study. Clin Transl Sci. 2022;15:2744\u201357. https:\/\/doi.org\/10.1111\/cts.13401.","journal-title":"Clin Transl Sci"},{"key":"1438_CR26","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1124\/jpet.123.001741","volume":"387","author":"M Rosenstock","year":"2023","unstructured":"Rosenstock M, et al. GlycoPEGylated FGF21 analog pegozafermin. J Pharmacol Exp Ther. 2023;387:204\u201313. https:\/\/doi.org\/10.1124\/jpet.123.001741.","journal-title":"J Pharmacol Exp Ther"},{"key":"1438_CR27","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/S2468-1253(22)00360-1","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba R, et al. Pegozafermin in non-alcoholic steatohepatitis. Lancet Gastroenterol Hepatol. 2023;8:120\u201332. https:\/\/doi.org\/10.1016\/S2468-1253(22)00360-1.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1438_CR28","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMoa2304286","volume":"389","author":"R Loomba","year":"2023","unstructured":"Loomba R, et al. Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH. N Engl J Med. 2023;389:998\u20131008. https:\/\/doi.org\/10.1056\/NEJMoa2304286.","journal-title":"N Engl J Med"},{"key":"1438_CR29","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1089\/thy.2009.0318","volume":"20","author":"M Castillo","year":"2010","unstructured":"Castillo M, et al. Impaired metabolic effects of a thyroid hormone receptor beta-selective agonist in a mouse model of diet-induced obesity. Thyroid. 2010;20:545\u201353. https:\/\/doi.org\/10.1089\/thy.2009.0318.","journal-title":"Thyroid"},{"key":"1438_CR30","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390:497\u2013509. https:\/\/doi.org\/10.1056\/NEJMoa2309000.","journal-title":"N Engl J Med"},{"key":"1438_CR31","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1016\/S0140-6736(07)61721-8","volume":"370","author":"R Christensen","year":"2007","unstructured":"Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007;370:1706\u201313. https:\/\/doi.org\/10.1016\/S0140-6736(07)61721-8.","journal-title":"Lancet"},{"key":"1438_CR32","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S0140-6736(05)66374-X","volume":"365","author":"LF Van Gaal","year":"2005","unstructured":"Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, R\u00f6ssner S, RIO-Europe Study Group. Effects of rimonabant on weight reduction and cardiovascular risk factors: the RIO-Europe study. Lancet. 2005;365:1389\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(05)66374-X.","journal-title":"Lancet"},{"key":"1438_CR33","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1089\/can.2025.0034","volume":"10","author":"J Matheson","year":"2025","unstructured":"Matheson J, Tertigas D, Malik S, et al. Feasibility and tolerability of nabilone for the treatment of obesity: a randomized controlled pilot trial. Cannabis Cannabinoid Res. 2025;10:640\u201351. https:\/\/doi.org\/10.1089\/can.2025.0034.","journal-title":"Cannabis Cannabinoid Res"},{"key":"1438_CR34","unstructured":"Regeneron Pharmaceuticals. Bimagrumab plus semaglutide enhances fat loss and muscle preservation. In: Regeneron. 2025. https:\/\/www.regeneron.com. Accessed 1 Nov 2025."},{"issue":"13","key":"1438_CR35","doi-asserted-by":"publisher","DOI":"10.1172\/JCI170885","volume":"133","author":"SJ Choi","year":"2024","unstructured":"Choi SJ, et al. The potential role of human endogenous retrovirus K in glioblastoma. J Clin Invest. 2024;(13):e12075688. https:\/\/doi.org\/10.1172\/JCI170885.","journal-title":"J Clin Invest"},{"key":"1438_CR36","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s41591-026-04204-0","volume":"32","author":"SB Heymsfield","year":"2026","unstructured":"Heymsfield SB, Aronne LJ, Montgomery P, et al. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. Nat Med. 2026;32:869\u201382. https:\/\/doi.org\/10.1038\/s41591-026-04204-0.","journal-title":"Nat Med"},{"key":"1438_CR37","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1210\/jc.2012-3692","volume":"98","author":"JT Dalton","year":"2013","unstructured":"Dalton JT, et al. Enobosarm improves lean body mass and function. J Clin Endocrinol Metab. 2013;98:199\u2013208. https:\/\/doi.org\/10.1210\/jc.2012-3692.","journal-title":"J Clin Endocrinol Metab"},{"key":"1438_CR38","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S1470-2045(13)70055-X","volume":"14","author":"AS Dobs","year":"2013","unstructured":"Dobs AS, Boccia RV, Croot CC, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol. 2013;14:335\u201345. https:\/\/doi.org\/10.1016\/S1470-2045(13)70055-X.","journal-title":"Lancet Oncol"},{"key":"1438_CR39","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000000518","volume":"8","author":"H Bedi","year":"2021","unstructured":"Bedi H, Hammond C, Sanders D, et al. Drug-induced liver injury from enobosarm (ostarine), a selective androgen receptor modulator. ACG Case Rep J. 2021;8:e00518. https:\/\/doi.org\/10.14309\/crj.0000000000000518.","journal-title":"ACG Case Rep J"},{"issue":"4","key":"1438_CR40","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/ijo.2016.192","volume":"41","author":"TH Collet","year":"2017","unstructured":"Collet TH, Litherland J, et al. Intra-gastric balloon as an adjunct to lifestyle support in severely obese adolescents; impact on weight, physical activity, cardiorespiratory fitness and psychosocial well-being. Int J Obes (Lond). 2017;41(4):163\u20139. https:\/\/doi.org\/10.1038\/ijo.2016.192.","journal-title":"Int J Obes (Lond)"},{"key":"1438_CR41","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.fitote.2013.07.003","volume":"90","author":"C Simmler","year":"2013","unstructured":"Simmler C, Pauli GF, Chen SN. Phytochemistry and properties of glabridin. Fitoterapia. 2013;90:160\u201384. https:\/\/doi.org\/10.1016\/j.fitote.2013.07.003.","journal-title":"Fitoterapia"},{"key":"1438_CR42","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1038\/s41591-025-03722-7","volume":"31","author":"M Noureddin","year":"2025","unstructured":"Noureddin M, et al. TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trial. Nat Med. 2025;31:2297\u2013305. https:\/\/doi.org\/10.1038\/s41591-025-03722-7.","journal-title":"Nat Med"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01438-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-026-01438-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01438-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T08:41:38Z","timestamp":1782463298000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-026-01438-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1438"],"URL":"https:\/\/doi.org\/10.1007\/s11883-026-01438-8","relation":{},"ISSN":["1534-6242"],"issn-type":[{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"BGT reports current or past consulting\/advisor fees from Novo Nordisk, Roman Health Ventures, Skye Bioscience, Circadian Care, Amgen, Lilly, Boehringer-Ingelheim, Gelesis, Cloud Health Systems, SAI MedPartners, Tern Pharmaceuticals, Alnu Health, and Intellihealth\/Flyte Health. MB and AR have no competing interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"66"}}